It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The therapeutic effects of C16, which is an inhibitor of RNA-dependent protein kinase (PKR), on growth of hepatocellular carcinoma (HCC) cells and tumor progression in vitro and in vivo were evaluated. Huh7 cells, a human HCC cell line, were used. The effects of C16 on cell viability were evaluated with the MTT assay, and real-time RT-PCR was performed. Huh7 cells were grafted into immunodeficient mice, and the in vivo effects of C16 on tumorigenesis were examined. C16 suppressed proliferation of HCC cells in a dose-dependent manner in vitro. Mouse models with xenograft transplantation showed that the inhibitor suppressed the growth of HCC cells in vivo. Moreover, C16 decreased angiogenesis in HCC tissue in the xenograft model. Consistent with these results in mice, transcript levels of vascular endothelial growth factor-A and factor-B, platelet-derived growth factor-A and factor-B, fibroblast growth factor-2, epidermal growth factor, and hepatocyte growth factor, which are angiogenesis-related growth factors, were significantly decreased by C16 in vitro. In conclusion, the PKR inhibitor C16 blocked tumor cell growth and angiogenesis via a decrease in mRNA levels of several growth factors. C16 may be useful in the treatment of HCC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon, Japan (GRID:grid.255464.4) (ISNI:0000 0001 1011 3808)
2 Department of Molecular Medicine for Pathogenesis, Graduate School of Medicine, Ehime University, Toon, Japan (GRID:grid.255464.4) (ISNI:0000 0001 1011 3808)
3 Department of Molecular Medicine for Pathogenesis, Graduate School of Medicine, Ehime University, Toon, Japan (GRID:grid.255464.4) (ISNI:0000 0001 1011 3808); Translational Research Center, Ehime University Hospital, Toon, Japan (GRID:grid.452478.8) (ISNI:0000 0004 0621 7227)
4 Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon, Japan (GRID:grid.255464.4) (ISNI:0000 0001 1011 3808); Department of Lifestyle-related Medicine and Endocrinology, Graduate School of Medicine, Ehime University, Toon, Japan (GRID:grid.255464.4) (ISNI:0000 0001 1011 3808)